Trial Outcomes & Findings for Evaluating the Transporter Protein Inhibitor Probenecid In Patients With Epilepsy (NCT NCT00610532)

Results Overview

Recruitment status

TERMINATED

Study phase

PHASE4

Target enrollment

8 participants

Primary outcome timeframe

end of each treatment

Results posted on

2013-05-14

Patients were recruited between Feb 2006 and Sept 2007.

Participant milestones
Measure	All Study Participants All study participants progressed from receiving intravenous phenytoin alone to intravenous phenytoin plus probenecid.
Intravenous Phenytoin Alone STARTED	8
Intravenous Phenytoin Alone COMPLETED	8
Intravenous Phenytoin Alone NOT COMPLETED	0
Intravenous Phenytoin Plus Probenecid STARTED	7
Intravenous Phenytoin Plus Probenecid COMPLETED	7
Intravenous Phenytoin Plus Probenecid NOT COMPLETED	0

Withdrawal data not reported

Evaluating the Transporter Protein Inhibitor Probenecid In Patients With Epilepsy

Baseline characteristics by cohort
Measure	All Study Participants n=8 Participants All study participants progressed from intravenous phenytoin alone to intravenous phenytoin plus probenecid
Age, Categorical <=18 years	0 Participants n=5 Participants
Age, Categorical Between 18 and 65 years	8 Participants n=5 Participants
Age, Categorical >=65 years	0 Participants n=5 Participants
Age Continuous	33 years STANDARD_DEVIATION 11.2 • n=5 Participants
Sex: Female, Male Female	0 Participants n=5 Participants
Sex: Female, Male Male	8 Participants n=5 Participants
Region of Enrollment United States	8 participants n=5 Participants

Timeframe: end of each treatment

Population: No data was analyzed because the study was terminated by the investigators after they decided not to continue the project

Outcome data not reported

Serious events: 0 serious events

Other events: 0 other events

Deaths: 0 deaths

Serious events: 0 serious events

Other events: 0 other events

Deaths: 0 deaths

Adverse event data not reported

Adverse event data not reported

The Ohio State University

Phone: 614-292-9713